Aspira Women's Health (AWH) 10-Q 14 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 30, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Registrant Name	VERMILLION, INC.
Entity Central Index Key	0000926617
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	vrml
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		75,580,474

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 6,174,000	$ 9,360,000
Accounts receivable	699,000	786,000
Prepaid expenses and other current assets	605,000	550,000
Inventories	98,000	92,000
Total current assets	7,576,000	10,788,000
Property and equipment, net	531,000	608,000
Other assets	147,000	12,000
Total assets	8,254,000	11,408,000
Current liabilities:
Accounts payable	1,157,000	950,000
Accrued liabilities	1,879,000	1,825,000
Short-term debt	190,000	189,000
Other current liabilities	110,000
Total current liabilities	3,336,000	2,964,000
Non-current liabilities:
Long-term debt	1,244,000	1,292,000
Other non-current liabilities	37,000
Total liabilities	4,617,000	4,256,000
Commitments and contingencies (Note 3)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at March 31, 2019 and December 31, 2018
Common stock, par value $0.001 per share, 150,000,000 shares authorized at March 31, 2019 and December 31, 2018; 75,532,748 and 75,501,394 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	75,000	75,000
Additional paid-in capital	414,202,000	414,001,000
Accumulated deficit	(410,640,000)	(406,924,000)
Total stockholders' equity	3,637,000	7,152,000
Total liabilities and stockholders' equity	$ 8,254,000	$ 11,408,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Condensed Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	75,532,748	75,501,394
Common stock, shares outstanding	75,532,748	75,501,394

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Revenue:
Revenue		$ 803	$ 649
Cost of revenue:
Cost of revenue	[1]	694	803
Gross profit (loss)		109	(154)
Operating expenses:
Research and development	[2]	209	142
Sales and marketing	[3]	2,364	1,225
General and administrative	[4]	1,255	1,314
Total operating expenses		3,828	2,681
Loss from operations		(3,719)	(2,835)
Interest income (expense), net		7	(12)
Other income (expense), net		(4)	(3)
Net loss		$ (3,716)	$ (2,850)
Net loss per share - basic and diluted		$ (0.05)	$ (0.05)
Weighted average common shares used to compute basic and diluted net loss per common share		75,507,532	60,037,161
Product [Member]
Revenue:
Revenue		$ 779	$ 613
Cost of revenue:
Cost of revenue	[1]	516	533
Service [Member]
Revenue:
Revenue		24	36
Cost of revenue:
Cost of revenue	[1]	$ 178	$ 270
[1]	Non-cash stock-based compensation expense included in cost of revenue and operating expenses: Cost of revenue $16, $30
[2]	Non-cash stock-based compensation expense included in cost of revenue and operating expenses: Research and development $2, $1
[3]	Non-cash stock-based compensation expense included in cost of revenue and operating expenses: Sales and marketing $22, $43
[4]	Non-cash stock-based compensation expense included in cost of revenue and operating expenses: General and administrative $144, $108

Consolidated Statements Of Oper

Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cost Of Revenue [Member]
Stock-based compensation expense	$ 16	$ 30
Research And Development [Member]
Stock-based compensation expense	2	1
Sales And Marketing [Member]
Stock-based compensation expense	22	43
General And Administrative [Member]
Stock-based compensation expense	$ 144	$ 108

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance (in shares) at Dec. 31, 2017		60,036,017
Balance at Dec. 31, 2017		$ 60	$ 399,400	$ (396,053)	$ 3,407
Net loss				(2,850)	(2,850)
ASC 606 Adjustment to retained earnings				500	500
Common stock issued for restricted stock awards (in shares)		3,321
Common stock issued for restricted stock awards			6		6
Stock compensation charge			176		176
Balance (in shares) at Mar. 31, 2018		60,039,338
Balance at Mar. 31, 2018		$ 60	399,582	(398,403)	1,239
Balance (in shares) at Dec. 31, 2018		75,501,394
Balance at Dec. 31, 2018		$ 75	414,001	(406,924)	7,152
Net loss				(3,716)	(3,716)
Common stock issued in conjuntion with exercise of stock options (in shares)		19,687
Common stock issued in conjuntion with exercise of stock options			17		17
Common stock issued for restricted stock awards (in shares)		11,667
Common stock issued for restricted stock awards			3		3
Stock compensation charge			181		181
Balance (in shares) at Mar. 31, 2019		75,532,748
Balance at Mar. 31, 2019		$ 75	$ 414,202	$ (410,640)	$ 3,637

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (3,716,000)	$ (2,850,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	124,000	186,000
Stock-based compensation expense	184,000	182,000
Loss on sale and disposal of property and equipment	1,000
Changes in operating assets and liabilities:
Accounts receivable	87,000	(58,000)
Prepaid expenses and other assets	(43,000)	10,000
Inventories	(6,000)
Accounts payable, accrued liabilities and other liabilities	261,000	173,000
Net cash used in operating activities	(3,108,000)	(2,357,000)
Cash flows from investing activities:
Purchase of property and equipment	(49,000)	(24,000)
Proceeds from sale of property and equipment	1,000
Net cash used in investing activities	(48,000)	(24,000)
Cash flows from financing activities:
Principal repayment of DECD loan	(47,000)	(46,000)
Repayment of capital lease obligations		(9,000)
Proceeds from issuance of common stock from exercise of stock options	17,000
Net cash used in financing activities	(30,000)	(55,000)
Net decrease in cash and cash equivalents	(3,186,000)	(2,436,000)
Cash and cash equivalents, beginning of period	9,360,000	5,539,000
Cash and cash equivalents, end of period	6,174,000	3,103,000
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	11,000	$ 12,000
Supplemental disclosure of noncash investing and financing activities:
Net increase in other assets/other liabilities for right of use assets	$ 147,000

Organization, Basis Of Presenta

Organization, Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	3 Months Ended
	Mar. 31, 2019
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company ,” “we” or “our ”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa,” respectively) through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. Liquidity The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $410,640,000 at March 31, 2019. The Company also expects to incur a net loss and negative cash flows from operations for 2019. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product and ASPiRA IVD sales to be the Company’s only material, recurring source of cash in 2019. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, equity offerings, debt financing, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the Company ’ s business, results of operations and financial condition. As discussed in Note 4, on April 17, 2018, the Company completed two public offerings (the “Offerings”) , pursuant to which certain investors purchased Vermillion common stock and Vermillion Series B convertible preferred stock for net proceeds of approximately $13,500,000 after deducting offering expenses. As discussed in Note 4, on August 31, 2017, certain investors exercised outstanding warrants to purchase shares of Vermillion common stock for net proceeds of approximately $3,577,000 after deducting offering expenses. As discussed in Note 4, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of Vermillion common stock for net proceeds of approximately $5,127,000 after deducting offering expenses. As discussed in Note 3, in March 2016, the Company entered into an agreement (the “Loan Agreement”) pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (the “DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. The loan may be prepaid at any time without premium or penalty.  Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31, 2018 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in Vermillion’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 28, 2019 (the “2018 Annual Report”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.  Significant Accounting and Reporting Policies Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) , which it adopted on January 1, 2018 using the modified retrospective method. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services.  Product Revenue The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of the test result to the prescribing physician. The entire transaction price is allocated to the single performance obligation contained in a contract with a patient. All revenue is recognized upon completion of the OVA1 or Overa test based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The Company also reviewed its patient account population and determined an appropriate distribution of patient accounts by payer ( i.e. , Medicare, patient pay, other third-party payer, etc .) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. There were no impairment losses on accounts receivable recorded during the three months ended March 31, 2019.  Service Revenue The Company’s service revenue is generated by performing IVD trial services for third-party customers. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation.  Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), Compensation - Stock Compensation (“ASU 2016-09”). The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The Company adopted this standard on January 1, 2018, and the adoption did not have a material impact on the consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Base Payment Accounting. This new guidance expands the scope of Topic 718 to include share-based payment transactions from acquiring goods and services from nonemployees, which was previously codified under Topic 505, where this change will modify the measurement requirements of nonemployee awards. This amendment is effective for annual periods after December 15, 2018. The Company adopted this standard on January 1, 2019 and its impact was not material. In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842 ) (“ASU 2016-2”) . This guidance is intended to make leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 will be effective for interim and annual periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited and early adoption is permitted. The Company adopted ASU 2016-02 effective January 1, 2019 and elected the package of practical expedients and the new transition approach permitted by ASU 2018-11. ASU 2018-11 allows the Company not to reassess existing identification of leases, classification of leases or any initial direct costs. The Company has also elected to use the hindsight practical expedient. The Company has two office leases which are required to be recorded as Right of Use (“ROU”) assets and corresponding lease liabilities on the balance sheet. The Company has no short term leases with terms of less than twelve months. The Company recognized ROU assets and a lease liability of approximately $178 ,000 related to its leases on its consolidated balance sheet as of January 1, 2019. The Company did not have a cumulative adjustment impacting retained earnings. In May 2014, the FASB issued ASC 606, which superseded existing revenue recognition guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 effective on January 1, 2018 using the modified retrospective method. Please see the above “Revenue Recognition” section for a discussion of the Company’s revenue recognition under ASC 606.

Agreements With Quest Diagnosti

Agreements With Quest Diagnostics Incorporated	3 Months Ended
	Mar. 31, 2019
Agreements With Quest Diagnostics Incorporated [Abstract]
Agreements With Quest Diagnostics Incorporated	2. AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED  In March 2015, the Company entered into a commercial agreement with Quest Diagnostics, Incorporated (“Quest Diagnostics”) . Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. Pursuant to this agreement, as amended as of March 1, 2018, Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 2019 in exchange for a market value fee. Per the terms of the commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers. As of the date of this Quarterly Report on Form 10-Q, we are in the process of renewing this agreement.

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies [Abstract]
Commitments And Contingencies	3. COMMITMENTS AND CONTINGENCIES  Development Loan On March 22, 2016, the Company entered into the Loan Agreement with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company’s Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. Under the terms of the Loan Agreement, as amended, the Company may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2021 (the “Measurement Date”). Conversely, if the Company is either unable to meet these job creation and retention milestones, namely, hiring and retaining for a consecutive two -year period 40 full-time employees with a specified average annual salary by the Measurement Date, or does not maintain the Company’s Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% of the total funded loan. An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty.  Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the CLIA laboratory used by ASPiRA LABS, is located in Austin, Texas, and the CLIA laboratory used by ASPiRA IVD is located in Trumbull, Connecticut. The Austin, Texas lease expires on January 31, 2020 with no automatic renewal or renewal option. In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately $596,000 . The term of the lease is five years beginning after the initial date of occupancy in January 2016 and a rent abatement period of five months, with two subsequent five -year renewal options at a rate equal to 90% of the then current fair market rate. As of the date of the implementation of the new lease standard, ASU 2016-2, the Company is not reasonably certain to exercise the renewal option for its Trumbull, Connecticut lease due to the uncertain nature of its pricing. The expense associated with these operating leases is shown in the table below (in thousands).     Three Months Ended March 31  Lease Cost Classification 2019 2018  Operating rent expense  Cost of revenue $ 9 $ 25  Research and development 4 7  Sales and marketing 8 12  General and administrative 11 22   Variable rent expense  Cost of revenue $ 12 $ 0  Research and development 3 0  Sales and marketing 10 0  General and administrative 14 1  Based on our leases as of March 31, 2019, the table below sets forth the approximate future lease payments related to operating leases with initial terms of one year or more (in thousands).    2019 $ 128  2020 40  2021 14  Total Operating Lease Payments 182  Less: Interest (4)  Present Value of Lease Liabilities 178   Weighted-average lease term and discount rate were as follows:    Weighted-average remaining lease term (in years) 1.5  Weighted-average discount rate 2.50%  Non-cancelable Royalty Obligations The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property . Under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500 . Royalty expense for the three months ended March 31, 2019 and 2018 totalled $31,000 and $24,000 , respectively.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity:
Stockholders' Equity	4. STOCKHOLDERS’ EQUITY  2018 Offerings On April 13, 2018, the Company entered into two underwriting agreements (each, an “Underwriting Agreement”) with Piper Jaffray & Co., as the sole underwriter (the “Underwriter”), in connection with separate but concurrent public offerings of the Company’s securities. Pursuant to the first Underwriting Agreement, the Company agreed to issue and sell an aggregate of 10,000,000 shares of Vermillion common stock, par value $0.001 per share, offered by the Underwriter in a public offering at a price to the public of $1.00 per share (the “Common Stock Offering”). Under this Underwriting Agreement, the Company granted the Underwriter an option to purchase up to an additional 1,500,000 shares of Vermillion common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The Underwriter did not exercise this option. The Common Stock Offering closed on April 17, 2018 and resulted in proceeds, net of 7% underwriting costs and other offering costs, to the Company of $8,992,000 . Pursuant to the second Underwriting Agreement, the Company agreed to issue and sell an aggregate of 50,000 shares of Vermillion Series B Convertible Preferred Stock, par value $0.001 per share, offered by the Underwriter in a public offering at a price to the public of $100.00 per share (the “Series B Offering”). The Series B Offering closed on April 17, 2018 and resulted in proceeds, net of 7% underwriting costs and other offering costs, to the Company of $4,496,000 . Upon obtaining Company stockholder approval at the annual meeting of Company stockholders on June 21, 2018, each of the 50,000 shares of Vermillion Series B Convertible Preferred Stock was automatically converted into shares of Vermillion common stock, at a conversion rate of 100 shares of Vermillion common stock per one share of Vermillion Series B Convertible Preferred Stock, including shares issuable pursuant to customary anti-dilution provisions. 2017 Warrant Repricing and Exercise In December 2014, the Company issued warrants to purchase up to an aggregate of 4,166,659 shares of Vermillion common stock at an exercise price of $2.00 per share in conjunction with a December 2014 private placement of Vermillion common stock . On August 31, 2017, certain holders of these warrants exercised warrants to purchase 3,796,818 shares of Vermillion common stock in consideration for the Company agreeing to reduce the exercise price to $1.00 per share of Vermillion common stock. The remaining 369,841 unexercised warrants expired by their original terms on December 23, 2017. The Company issued 3,796,818 shares of Vermillion common stock and received $ 3,796,818 in aggregate gross proceeds (approximately $3,577,000 net of transaction costs). The incremental non-cash fair value of approximately $942,000 from the modification of the warrants was calculated using the Black-Scholes model and recorded as a deemed dividend to the warrant holders within stockholders’ equity.  2017 Private Placement On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of Vermillion common stock at a price of $0.125 per warrant share in the private placement. Net proceeds of the private placement were approximately $5,127,000 after deducting offering expenses. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share. The warrants expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . The sale of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is $804,000 and to the common stock is approximately $4,323,000 .  2010 Stock Incentive Plan The Company’s employees, directors, and consultants are eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to 12,122,983 shares of Vermillion common stock, subject to adjustment as provided in the 2010 Plan.  Stock-Based Compensation During the three months ended March 31, 2019 , the Company awarded Vermillion’s non-employee directors an aggregate of 190,909 shares of restricted stock under the 2010 Plan having a fair value of approximately $252,000 . The vesting of these shares of restricted stock is as follows: 25% on April 1, 2019, 25% on June 1, 2019, 25% on September 1, 2019 and 25% on December 1, 2019. During the three months ended March 31, 2019, the Company also granted Vermillion’s non-employee directors options to purchase an aggregate of 402,584 shares of Vermillion common stock with an exercise price of $1.29 per share. During the three months ended March 31, 2019, the Company awarded certain consultants 11,667 shares of restricted stock under the 2010 Plan having a fair value of approximately $10,000 . During the three months ended March 31, 2019, the Company also granted certain consultants options to purchase 50,000 shares of Vermillion common stock with an exercise price of $0.47 per share. These stock options have performance-based vesting based on certain metrics through March 31, 2020 . The Company also granted certain consultants options to purchase an aggregate of 100,000 shares of Vermillion common stock with an exercise price of $1.29 per share. During the three months ended March 31, 2019, the Company granted certain officers and employees options to purchase an aggregate of 575,000 shares of Vermillion common stock with an exercise price of $0.47 per share. These stock options have performance-based vesting based on certain metrics through March 31, 2020 . The Company also granted certain officers and employees options to purchase an aggregate of 55,000 shares of Vermillion common stock with an exercise price of $0.71 per share, 125,000 shares of Vermillion common stock with an exercise price of $0.77 and 1,073,000 shares of Vermillion common stock with an exercise price of $1.29 per share. These stock options vest 25% on each of the four anniversaries of the vesting commencement date for each such stock option. The allocation of employee stock-based compensation expense by functional area for the three months ended March 31, 2019 and 2018 was as follows:   Three Months Ended  March 31,  (in thousands) 2019 2018  Cost of revenue $ 12 $ 24  Research and development 2 1  Sales and marketing 20 47  General and administrative 143 139  Total $ 177 $ 211 

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2019
Loss Per Share [Abstract]
Loss Per Share	5. LOSS PER SHARE The Company calculates basic loss per share using the weighted average number of shares of Vermillion common stock outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the weighted average number of shares of Vermillion common stock outstanding and excludes the effects of 10,144,433 and 7, 419,718 potential shares of Vermillion common stock as of March 31, 2019 and 2018, respectively, that are anti-dilutive. Potential shares of Vermillion common stock include incremental shares of Vermillion common stock issuable upon the exercise of outstanding warrants, stock options and unvested restricted stock units.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	6. RELATED PARTY TRANSACTIONS On December 18, 2017, the Company entered into a consulting agreement for a term of up to five months with the Company’s former Senior Vice President, Finance and Chief Accounting Officer. Pursuant to the terms of the consulting agreement through May 15, 2018, the consultant provided accounting and finance services related to the transition of financial leadership . The Company agreed to pay $150 per hour for such consulting services. The consultant also remained eligible for payout under the Company’s 2017 Corporate Incentive Plan after he satisfactorily met certain performance obligations as outlined in the consulting agreement. During the three months ended March 31, 2019 and 2018, the consultant was paid an aggregate of none and $45,675 for services provided pursuant to the consulting agreement. 

Organization, Basis Of Presen_2

Organization, Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Policy)	3 Months Ended
	Mar. 31, 2019
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company ,” “we” or “our ”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa,” respectively) through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays.
Liquidity	Liquidity The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $410,640,000 at March 31, 2019. The Company also expects to incur a net loss and negative cash flows from operations for 2019. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product and ASPiRA IVD sales to be the Company’s only material, recurring source of cash in 2019. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, equity offerings, debt financing, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the Company ’ s business, results of operations and financial condition. As discussed in Note 4, on April 17, 2018, the Company completed two public offerings (the “Offerings”) , pursuant to which certain investors purchased Vermillion common stock and Vermillion Series B convertible preferred stock for net proceeds of approximately $13,500,000 after deducting offering expenses. As discussed in Note 4, on August 31, 2017, certain investors exercised outstanding warrants to purchase shares of Vermillion common stock for net proceeds of approximately $3,577,000 after deducting offering expenses. As discussed in Note 4, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of Vermillion common stock for net proceeds of approximately $5,127,000 after deducting offering expenses. As discussed in Note 3, in March 2016, the Company entered into an agreement (the “Loan Agreement”) pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (the “DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. The loan may be prepaid at any time without premium or penalty. 
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31, 2018 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in Vermillion’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 28, 2019 (the “2018 Annual Report”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.
Significant Accounting and Reporting Policies	Significant Accounting and Reporting Policies Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) , which it adopted on January 1, 2018 using the modified retrospective method. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services.  Product Revenue The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of the test result to the prescribing physician. The entire transaction price is allocated to the single performance obligation contained in a contract with a patient. All revenue is recognized upon completion of the OVA1 or Overa test based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The Company also reviewed its patient account population and determined an appropriate distribution of patient accounts by payer ( i.e. , Medicare, patient pay, other third-party payer, etc .) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. There were no impairment losses on accounts receivable recorded during the three months ended March 31, 2019.  Service Revenue The Company’s service revenue is generated by performing IVD trial services for third-party customers. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), Compensation - Stock Compensation (“ASU 2016-09”). The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The Company adopted this standard on January 1, 2018, and the adoption did not have a material impact on the consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Base Payment Accounting. This new guidance expands the scope of Topic 718 to include share-based payment transactions from acquiring goods and services from nonemployees, which was previously codified under Topic 505, where this change will modify the measurement requirements of nonemployee awards. This amendment is effective for annual periods after December 15, 2018. The Company adopted this standard on January 1, 2019 and its impact was not material. In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842 ) (“ASU 2016-2”) . This guidance is intended to make leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 will be effective for interim and annual periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited and early adoption is permitted. The Company adopted ASU 2016-02 effective January 1, 2019 and elected the package of practical expedients and the new transition approach permitted by ASU 2018-11. ASU 2018-11 allows the Company not to reassess existing identification of leases, classification of leases or any initial direct costs. The Company has also elected to use the hindsight practical expedient. The Company has two office leases which are required to be recorded as Right of Use (“ROU”) assets and corresponding lease liabilities on the balance sheet. The Company has no short term leases with terms of less than twelve months. The Company recognized ROU assets and a lease liability of approximately $178 ,000 related to its leases on its consolidated balance sheet as of January 1, 2019. The Company did not have a cumulative adjustment impacting retained earnings. In May 2014, the FASB issued ASC 606, which superseded existing revenue recognition guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 effective on January 1, 2018 using the modified retrospective method. Please see the above “Revenue Recognition” section for a discussion of the Company’s revenue recognition under ASC 606.

Commitments And Contingencies (

Commitments And Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies [Abstract]
Expense Associated with Operating Leases	   Three Months Ended March 31  Lease Cost Classification 2019 2018  Operating rent expense  Cost of revenue $ 9 $ 25  Research and development 4 7  Sales and marketing 8 12  General and administrative 11 22   Variable rent expense  Cost of revenue $ 12 $ 0  Research and development 3 0  Sales and marketing 10 0  General and administrative 14 1 
Future Lease Payments Related to Operating Leases	  2019 $ 128  2020 40  2021 14  Total Operating Lease Payments 182  Less: Interest (4)  Present Value of Lease Liabilities 178 
Weighted-Average Lease Term and Discount Rate	   Weighted-average remaining lease term (in years) 1.5  Weighted-average discount rate 2.50% 

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity:
Allocation of Stock-Based Compensation Expense by Functional Area	  Three Months Ended  March 31,  (in thousands) 2019 2018  Cost of revenue $ 12 $ 24  Research and development 2 1  Sales and marketing 20 47  General and administrative 143 139  Total $ 177 $ 211 

Organization, Basis Of Presen_3

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details)	Jan. 01, 2019USD ($)contract	Apr. 17, 2018USD ($)item	Aug. 31, 2017USD ($)	Feb. 17, 2017USD ($)	Apr. 15, 2016USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Mar. 22, 2016USD ($)
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit						$ (410,640,000)	$ (406,924,000)
Number of completed public offerings | item		2
Proceeds from exercise of common stock warrants, net of issuance costs			$ 3,577,000
Proceeds from public offering		$ 13,500,000
Proceeds from issuance of private placement				$ 5,127,000
Impairment losses						0
Operating lease liability						$ 178,000
DECD [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
DECD maximum borrowing capacity								$ 4,000,000
DECD initial disbursement					$ 2,000,000
DECD remaining borrowing capacity								$ 2,000,000
Accounting Standards Update 2016-02 [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Number of operating office leases | contract	2
Operating lease right-of-use Assets	$ 178,000
Operating lease liability	$ 178,000

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details)	Apr. 15, 2016USD ($)	Mar. 22, 2016USD ($)employee	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Oct. 31, 2015USD ($)
Commitments And Contingencies [Line Items]
Percent of royalty paid			4.00%
Minimum royalty payment			$ 57,500
Royalty expense			$ 31,000	$ 24,000
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Leasehold improvements					$ 596,000
Lease term			5 years
Rent abatement period			5 months
Lease renewal term			5 years
DECD [Member]
Commitments And Contingencies [Line Items]
DECD maximum borrowing capacity		$ 4,000,000
Fixed rate per annum		2.00%
Maturity date			Apr. 15, 2026
Amount eligible for forgiveness		$ 2,000,000
Job creation, consecutive period of hiring and retaining		2 years
Job creation, number of employees | employee		40
Debt, maturity term			10 years
Debt penalty percentage			5.00%
DECD initial disbursement	$ 2,000,000
DECD remaining borrowing capacity		$ 2,000,000

Commitments And Contingencies_3

Commitments And Contingencies (Expense Associated with Operating Leases) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cost Of Revenue [Member]
Operating rent expense	$ 9	$ 25
Variable rent expense	12	0
Research And Development [Member]
Operating rent expense	4	7
Variable rent expense	3	0
Sales And Marketing [Member]
Operating rent expense	8	12
Variable rent expense	10	0
General And Administrative [Member]
Operating rent expense	11	22
Variable rent expense	$ 14	$ 1

Commitments And Contingencies_4

Commitments And Contingencies (Future Lease Payments Related to Operating Leases) (Details) $ in Thousands	Mar. 31, 2019USD ($)
Operating Lease Liabilities, Payments Due [Abstract]
2019	$ 128
2020	40
2021	14
Total Operating Lease Payments	182
Less: Interest	(4)
Present Value of Lease Liabilities	$ 178

Commitments And Contingencies_5

Commitments And Contingencies (Weighted-Average Lease Term and Discount Rate) (Details)	Mar. 31, 2019
Leases [Abstract]
Weighted-average remaining lease term (in years)	1 year 6 months
Weighted-average discount rate	2.50%

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details)	Jun. 21, 2018shares	Apr. 17, 2018USD ($)	Apr. 13, 2018agreement$ / sharesshares	Dec. 23, 2017shares	Aug. 31, 2017USD ($)$ / sharesshares	Feb. 17, 2017USD ($)$ / sharesshares	Dec. 31, 2014$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued								75,532,748	75,501,394
Price per share | $ / shares								$ 0.001	$ 0.001
Proceeds from issuance of private placement | $						$ 5,127,000
Proceeds from public offering | $		$ 13,500,000
Fair value of warrants issued | $						$ 804,000
Common stock value | $								$ 75,000	$ 75,000
Preferred stock, shares issued								0	0
Preferred stock, par value | $ / shares								$ 0.001	$ 0.001
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant								12,122,983
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted								190,909
Fair value of restricted share units | $								$ 252,000
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | April 1, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage								25.00%
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | June 1, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage								25.00%
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | September 1, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage								25.00%
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | December 1, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage								25.00%
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | $1.29 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								402,584
Stock options granted, average exercise price | $ / shares								$ 1.29
2010 Stock Incentive Plan [Member] | Certain Consultants [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted								11,667
Fair value of restricted share units | $								$ 10,000
2010 Stock Incentive Plan [Member] | Certain Consultants [Member] | $0.47 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								50,000
Stock options granted, average exercise price | $ / shares								$ 0.47
2010 Stock Incentive Plan [Member] | Certain Consultants [Member] | $1.29 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								100,000
Stock options granted, average exercise price | $ / shares								$ 1.29
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | Stock Option [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage								25.00%
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $0.47 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								575,000
Stock options granted, average exercise price | $ / shares								$ 0.47
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $0.71 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								55,000
Stock options granted, average exercise price | $ / shares								$ 0.71
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $0.77 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								125,000
Stock options granted, average exercise price | $ / shares								$ 0.77
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $1.29 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								1,073,000
Stock options granted, average exercise price | $ / shares								$ 1.29
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercised								19,687
2018 Offerings [Member] | Series B Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriting agreement, per share | $ / shares			$ 100
Proceeds from public offering | $		$ 4,496,000
Preferred stock, shares issued			50,000
Preferred stock, par value | $ / shares			$ 0.001
Percentage of underwriting costs and other offering costs		7.00%
Shares converted	50,000
2018 Offerings [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of underwriting agreements | agreement			2
Common stock, shares issued			10,000,000
Price per share | $ / shares			$ 0.001
Underwriting agreement, per share | $ / shares			$ 1
Underwriting agreement			1,500,000
Proceeds from public offering | $		$ 8,992,000
Common stock issuable per preferred share	100
Percentage of underwriting costs and other offering costs								7.00%
2017 Warrant Repricing And Exercise [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued					3,796,818
Warrants issued in connection with private placement							4,166,659
Warrants exercised					3,796,818
Warrants unexercised				369,841
Proceeds from issuance of private placement | $					$ 3,577,000
Incremental non-cash fair value of warrants | $					$ 942,000
Exercise price of warrants | $ / shares					$ 1		$ 2
Gross proceeds from issuance of private placement | $					$ 3,796,818
2017 Private Placement [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued						3,747,125
Price per share | $ / shares						$ 1.40
Issued a warrant to purchase common stock with a cost | $ / shares						$ 0.125
Proceeds from issuance of private placement | $						$ 5,127,000
Warrants outstanding to purchase shares						2,810,338
Exercise price of warrants | $ / shares						$ 1.80
Common stock value | $						$ 4,323,000

Stockholders' Equity (Allocatio

Stockholders' Equity (Allocation of Stock-Based Compensation Expense by Functional Area) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 16	$ 30
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2	1
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	22	43
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	144	108
Employee Stock-Based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	177	211
Employee Stock-Based Compensation [Member] | Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	12	24
Employee Stock-Based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2	1
Employee Stock-Based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	20	47
Employee Stock-Based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 143	$ 139

Loss Per Share (Details)

Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Loss Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	10,144,433	7,419,718

Related Party Transactions (Det

Related Party Transactions (Details) - Former Senior Vice President, Finance And Chief Accounting Officer [Member] - USD ($)	Dec. 18, 2017	Mar. 31, 2019	Mar. 31, 2018
Related Party Transaction [Line Items]
Term of consulting agreement	5 months
Payment per hour	$ 150
Payments to related party		$ 0	$ 45,675